Weight Loss with Erdheim-Chester Disease in South Africa

Erdheim-Chester disease was first described in 1930 by Jakob Erdheim and William Chester. For decades it was considered vanishingly rare, with only a few hundred cases in the literature. However, improved diagnostic tools — particularly the recognition of the BRAF V600E mutation in 2012 — have dramatically increased diagnosis rates, and the true prevalence is likely higher than historical estimates suggest. It primarily affects adults aged 40–70, with a slight male predominance.

ECD is now classified as a neoplastic disorder — a clonal proliferation of myeloid precursor cells driven by somatic mutations in the MAPK pathway (most commonly BRAF V600E, but also NRAS, KRAS, MAP2K1, and others). This reclassification has transformed treatment, moving from ineffective chemotherapy to highly effective targeted therapies.

This article is for educational purposes only. ECD management requires a haematologist or oncologist with rare disease experience. Dietary changes must be discussed with your treating team.

How ECD Affects Weight and Metabolism

Systemic Inflammation and Cachexia

ECD drives chronic systemic inflammation through excess production of pro-inflammatory cytokines — particularly interleukin-6 (IL-6), TNF-alpha, and interferon-gamma. This cytokine storm can cause:

• Inflammatory cachexia: Loss of muscle and fat despite adequate calorie intake — the cytokine environment drives catabolism even when you are eating well. This is the most common weight direction in active, untreated ECD.
• Fatigue: Profound and often treatment-limiting; drastically reduces physical activity
• Anaemia of chronic inflammation: Reduces exercise capacity and energy

Hypothalamic Involvement

In roughly 25–30% of ECD patients, histiocytes infiltrate the hypothalamus and/or pituitary gland. This causes:

• Central diabetes insipidus: Inability to concentrate urine, causing extreme thirst and polyuria — managed with desmopressin (DDAVP), available in South Africa
• Panhypopituitarism: Deficiency of multiple pituitary hormones — growth hormone, TSH, ACTH, LH/FSH — each of which can independently cause weight gain, fatigue, and metabolic disturbance
• Hypothalamic obesity: In some cases, hypothalamic damage disrupts satiety signalling, causing hyperphagia and rapid weight gain that is extremely resistant to conventional calorie restriction

Renal Involvement: The Hairy Kidney Sign

Perirenal and retroperitoneal infiltration is the most common ECD manifestation, seen in up to 90% of patients on PET-CT. The "hairy kidney" appearance on imaging reflects histiocyte infiltration around the kidneys. Renal involvement can cause:

• Chronic kidney disease (CKD) — which significantly constrains protein intake in dietary management
• Hypertension from renal artery involvement
• Fluid retention

Cardiovascular Involvement

Pericardial infiltration, aortic involvement ("coated aorta"), and right atrial pseudotumours are well-documented. These can impair cardiac function and severely limit exercise tolerance.

Treatment Side Effects

The two main treatments significantly affect weight:

• Vemurafenib (BRAF inhibitor): Can cause photosensitivity, joint pain, and skin toxicity — but also sometimes causes mild weight loss through nausea and appetite suppression
• Cobimetinib (MEK inhibitor, used with vemurafenib): GI side effects common
• Interferon-alpha (IFN-α): Historically used; causes significant fatigue, depression, and weight loss (not beneficial weight loss — inflammatory cachexia)
• Corticosteroids (used for certain manifestations): Classic cause of weight gain, fluid retention, central adiposity, and insulin resistance

Understanding Which Weight Direction You Are Facing

Before planning weight management for ECD, you need to understand which direction your weight is going and why — because the strategies are almost opposite:

Dietary Strategy for ECD-Related Weight Gain

The following assumes your ECD is under treatment control and you are managing secondary weight gain (from steroids, hypothalamic involvement, or reduced activity). If you are losing weight unintentionally, the priority is adequate nutrition, not a calorie deficit.

Anti-Inflammatory Foundation

Regardless of weight direction, an anti-inflammatory dietary pattern is warranted given the central role of inflammation in ECD pathophysiology. The Mediterranean diet has the strongest evidence base:

Steroid-Specific Dietary Adjustments

If you are on corticosteroids, these specific adjustments are critical:

• Low sodium diet: Steroids promote sodium and fluid retention — reduce salt, avoid Aromat, biltong, tinned soups, processed meats, and stock cubes. Target below 2 g sodium per day.
• High potassium foods: Counter steroid-induced hypokalaemia — avocado, sweet potato, banana, spinach, lentils
• Low glycaemic index carbohydrates: Steroids worsen insulin resistance and blood sugar — choose oats, brown rice, sweet potato over white bread, white rice, sugary cereals
• Adequate calcium and vitamin D: Steroids deplete bone — low-fat dairy, fortified milk alternatives, sardines (with bones), sun exposure. Consider supplementation with treating doctor's guidance.
• Protein priority: Steroids cause muscle catabolism — prioritise protein at each meal (eggs, legumes, fish, chicken) to counteract this

Hypothalamic Obesity Management

If hypothalamic damage is the driver of weight gain, conventional calorie restriction is typically ineffective because the homeostatic feedback system is broken. Strategies with some evidence:

• Structured meal times with no snacking between meals — removes opportunity for hyperphagia to express itself
• High-protein, high-fibre meals — maximise peripheral satiety signals from gut hormones and stretch receptors
• GLP-1 receptor agonists (semaglutide/Ozempic, liraglutide): Some case series in hypothalamic obesity show meaningful benefit; discuss with your endocrinologist
• Hormone replacement: Replacing deficient pituitary hormones (thyroid, sex hormones, growth hormone) can normalise metabolic rate

Exercise with ECD: Working Within Cardiac and Bone Limits

Before Starting Exercise

ECD can affect the heart, lungs, and bones. Before beginning any exercise programme:

• Confirm cardiac status with echocardiogram and ECG
• Bone assessment — ECD causes sclerotic bone lesions (long bone involvement); high-impact activity may be contraindicated
• Pulmonary function tests if there is any known lung involvement

Recommended Activity Types

• Swimming and aqua aerobics: No bone loading, excellent cardiovascular work, available at most SA municipal facilities
• Walking: Low impact, progressive — start with 15 minutes daily and build by 5 minutes per week as tolerated
• Cycling (stationary bike): Low joint impact, cardiovascular benefit, can be monitored for exertion level
• Light resistance training: Upper body focus if lower limb bone involvement; resistance bands are safe and inexpensive

Managing Fatigue-Limited Activity

ECD-related fatigue is inflammatory in origin and does not respond to "pushing through." Use pacing strategies:

• Exercise at your best-energy time of day (usually morning for most ECD patients)
• Short sessions (15–20 minutes) more frequently rather than long sessions
• Rate exertion on a 0–10 scale — aim for 4–6, not 8+
• Rest days are legitimate — chronic fatigue conditions require planned recovery

Monitoring During Weight Management

Getting Care in South Africa

ECD is rare enough that dedicated clinics do not exist in South Africa. Practical approach:

• Haematology/oncology referral: ECD is now managed as a neoplastic condition — haematologists at academic hospitals (Charlotte Maxeke, Tygerberg, Inkosi Albert Luthuli, Steve Biko) are the most appropriate specialists
• BRAF testing: If not yet tested, insist on BRAF V600E testing of biopsy material — this determines eligibility for vemurafenib, which is transformative for BRAF-positive patients
• Access to vemurafenib: Registered in South Africa (Zelboraf) for melanoma — ECD use is off-label but compassionate use applications are possible; some medical aids will cover with specialist motivation
• Histiocyte Society: International organisation (histiocytesociety.org) maintains a specialist directory and can connect South African patients with expert consultants for telemedicine reviews

Key Takeaways

• Erdheim-Chester disease is a clonal histiocytic disorder driven by MAPK pathway mutations — 50–70% BRAF V600E positive
• Chronic systemic inflammation can cause cachexia — not all ECD patients need to lose weight; establish which direction your weight is going and why
• Hypothalamic/pituitary involvement causes hormone deficiencies and hypothalamic obesity — requires hormone replacement and specialist management, not just calorie restriction
• Corticosteroid-related weight gain requires low-sodium, low-GI eating with adequate protein and calcium
• Anti-inflammatory Mediterranean diet benefits all ECD patients regardless of weight direction
• Cardiac and bone assessment before starting exercise — swimming and walking are the safest starting points
• Sun protection is non-negotiable on BRAF inhibitor therapy in the South African climate